Literature DB >> 28093644

Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit.

P Joret-Descout1, S Dauger2,3,4, M Bellaiche5, O Bourdon1,6,7, S Prot-Labarthe8,9,10.   

Abstract

Background Stress ulcer prophylaxis (SUP) is recommended in some situations to prevent upper gastrointestinal bleeding and is a component of standard care for patients admitted to the intensive care unit (ICU). Proton pump inhibitors (PPIs), already among the most widely prescribed drug classes, are being increasingly used. Objective To describe PPI prescribing patterns and their changes after the dissemination of guidelines. Setting Paediatric ICU (PICU), Robert-Debré Teaching Hospital, Paris, France, which admits about 800 patients annually, from full-term neonates to 18-year-olds. Method Prospective observational study with two 6-week observation periods (July-August and September-October, 2013), before and after dissemination in the PICU of PPI prescribing guidelines. Main outcome measure Changes in PPI prescribing patterns (prevalence, dosage, and indication) after the guidelines. Results The number of patients admitted to the PICU was 77 (mean age 4.6 years [range 1 day-18 years]) before and 70 (mean age 3.8 years [range 1 day-17 years]) after the guidelines. During both periods, SUP was the most common reason for PPI prescribing. The proportion of patients prescribed PPIs dropped significantly, from 51% before the guidelines to 30% after the guidelines (p < 0.001). Mean daily dosage also decreased significantly, from 1.5 mg/kg/(range 0.5-4.4) to 1.1 mg/kg (range 0.7-1.8) (p < 0.002). None of the patients experienced upper gastrointestinal bleeding during either period. Conclusion Off-label PPI prescribing for SUP was common in our PICU. The introduction of guidelines was associated with a significant decrease in PPI use and dosage. This study confirms that guidelines can change PPI prescribings patterns in paediatric practice.

Entities:  

Keywords:  Drug prescriptions; France; Guidelines; Intensive care unit; Off-label prescribing; Pediatrics; Proton pump inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28093644     DOI: 10.1007/s11096-016-0420-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  32 in total

1.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.

Authors:  Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor
Journal:  Arch Intern Med       Date:  2010-05-10

2.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

3.  An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia.

Authors:  Jorge Enrique Machado-Alba; Juan Daniel Castrillón-Spitia; Manuel José Londoño-Builes; Alejandra Fernández-Cardona; Carlos Felipe Campo-Betancourth; Sergio Andrés Ochoa-Orozco; Luis Felipe Echeverri-Cataño; Joaquín Octavio Ruiz-Villa; Andrés Gaviria-Mendoza
Journal:  Rev Esp Enferm Dig       Date:  2014-02       Impact factor: 2.086

4.  Pediatric risk of mortality (PRISM) score.

Authors:  M M Pollack; U E Ruttimann; P R Getson
Journal:  Crit Care Med       Date:  1988-11       Impact factor: 7.598

5.  Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress.

Authors:  Kurt Lenz; Robert Buder; Fritz Firlinger; Gerald Lohr; Martin Voglmayr
Journal:  Wien Klin Wochenschr       Date:  2014-11-20       Impact factor: 1.704

Review 6.  Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis.

Authors:  Waleed Alhazzani; Farhan Alenezi; Roman Z Jaeschke; Paul Moayyedi; Deborah J Cook
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

7.  Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada.

Authors:  Jeffrey F Barletta; Salmaan Kanji; Robert MacLaren; Ishaq Lat; Brian L Erstad
Journal:  J Crit Care       Date:  2014-06-30       Impact factor: 3.425

8.  Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.

Authors:  Robert MacLaren; Paul M Reynolds; Richard R Allen
Journal:  JAMA Intern Med       Date:  2014-04       Impact factor: 21.873

9.  Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN).

Authors:  Yvan Vandenplas; Colin D Rudolph; Carlo Di Lorenzo; Eric Hassall; Gregory Liptak; Lynnette Mazur; Judith Sondheimer; Annamaria Staiano; Michael Thomson; Gigi Veereman-Wauters; Tobias G Wenzl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-10       Impact factor: 2.839

10.  Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.

Authors:  Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

View more
  3 in total

Review 1.  A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children.

Authors:  Valeria Dipasquale; Giuseppe Cicala; Edoardo Spina; Claudio Romano
Journal:  Front Pharmacol       Date:  2022-02-10       Impact factor: 5.810

Review 2.  Development of an evaluation indicator system for the rational use of proton pump inhibitors in pediatric intensive care units: An application of Delphi method.

Authors:  Xiaofeng Ni; Mao Lin; Jialian Li; Linan Zeng; Wenrui Li; Liang Huang; Deyuan Li; Lingli Zhang
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

3.  Natural history of gastroesophageal reflux in infancy: new data from a prospective cohort.

Authors:  Marlène Curien-Chotard; Prévost Jantchou
Journal:  BMC Pediatr       Date:  2020-04-07       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.